Amarin Corp plc (ADR)

NASDAQ: AMRN
$6.86
-$0.17 (-2.4%)
Closing price August 5, 2020
Amarin reported its latest quarterly results on Tuesday morning and gave an update on the most recent developments with its blockbuster drug Vascepa.
Is it time to buy Amarin? The biopharmaceutical company just announced a new study showing its drug Vascepa can significantly reduce cardiovascular risk in people with diabetes.
Among the items on the annual shareholders meeting agenda are the usual proposals. The board also has submitted a new stock incentive plan to replace the existing one that expires next year.
Amarin is on hold as generic rivals seek to copy its potential blockbuster Vascepa.
Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the pandemic.
While Amarin supports research into Vascepa's possible use in treating COVID-19, the financial benefits promise to be greater if Vascepa's patents are upheld. Of course, Wall Street is bound to lift...
Amarin’s Vascepa treats cardiovascular disease, which is a big risk factor for COVID-19 patients, but is the subject of patent litigation.
Amarin will trial Vascepa as a COVID-19 treatment and that could more than offset investor concerns about patent litigation.
Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing on the stock.
There are still a lot of questions for Amarin must figure out before it gets back on track. For investors, the question is whether it is the market recovery that is lifting the stock instead of the...
Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that blocked its patents on the medication Vascepa, the company’s chief executive says....
Amarin has two big problems. Getting an unfavorable court decision overruled is by far the more important.
Amarin stock was absolutely crushed at the tail end of March, and now the company is dealing with the fallout. Investors will be asking a lot of tough questions. Namely, is Amarin viable going...
Until late Monday, Amarin continued to get good news relevant to Vascepa, its treatment for cardiovascular disease. The big news, though, was lurking in Nevada federal district court.
Tuesday's top analyst upgrades and downgrades included Apache, Broadcom, Caterpillar, Dollar General, Microsoft, NXP Semiconductors, Salesforce.com, Sirius XM, Slack and Yelp.